Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008474
Chunk: 68

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 68
---
 could lead to costly litigation for us and make an investment in us less appealing.

The market price of our common stock may fluctuate substantially due to a variety of factors, including:

| ● | the                                                                  
 status and results of our clinical trials for our product candidate; |

| ● | our                                                                                                                                
 ability to fund and complete our study and, if such study provides data supporting an FDA submission, our ability to apply for and 
 obtain clearance from the FDA;                                                                                                     |

| ● | our                                     
 ability to remain a going concern;      |
| ● | our                                     
 ability to maintain our Nasdaq listing; |

| ● | our                          
 business strategy and plans; |

| ● | the                                                                           
 potential market for our product candidate, if approved for sale in the U.S.; |

| ● | new                                                                                                
 regulatory pronouncements and changes in regulatory guidelines and timing of regulatory approvals; |

| ● | general                                    
 and industry-specific economic conditions; |

| ● | variations                                                                                                                   
 in our quarterly financial and operating results, including the rate at which we incur negative cash flow in future periods; |

| ● | additions                              
 to or departures of our key personnel; |

| ● | changes                                                                                           
 in market valuations of other companies that operate in our business segments or in our industry; |

| ● | lack                  
 of trading liquidity; |

| ● | if                                                                                                                            
 our product is approved and becomes available for us to sell in the U.S., whether we ultimately achieve profitability or not; |

| ● | changes                       
 in accounting principles; and |

| ● | general                                                 
 market conditions, economic and other external factors. |

The market prices of the securities of early-stage companies, particularly companies like ours that are seeking to obtain regulatory approval of their product candidate and do not yet generate operating revenue, have been highly volatile and are likely to remain highly volatile in the future. This volatility has often been unrelated to the operating performance of particular companies. In the past, companies that experience volatility in the market price of their securities have often faced securities class action litigation. Whether or not meritorious, litigation brought against us could result in substantial costs, divert our management’s attention and resources and harm our financial condition and results of operations.

| 51 |

Although we have no preferred stock outstanding as of the date hereof and we have currently no intention to issue any preferred stock, our common stockholders could be adversely affected by the issuance by us of preferred stock in the future, if any.

Our certificate of incorporation does not restrict our